The Biolink Group’s main operating area is drug discovery, research and development of medicines based on synthesized, patented anthocyanin molecules and their metabolites. Clinical research based on the synthetic anthocyanin molecules has been taking place since 2005.

The Biolink Group does develop drug candidates to a stage where satisfactory value has been established and sufficient proof in animals and/or man has been documented. Our strategy is to contract, or to enter into strategic partnerships with, established pharmaceutical companies to perform further clinical trials and commercialization of the drug products.

Biolink Group also has a consumer-based operation, developing and marketing the professional dietary supplement product, Medox®. This unique dietary supplement is based on a wide range of clinical research and documentation at university hospitals and universities in an international environment. Medox® is mainly marketed through professional health care workers. The product is based on Biolink Group`s registered clinical test substance, MP865®.

The Biolink Group supplies pure natural anthocyanin molecules and other polyphenols to medical and biotechnological research hospitals and research organizations in more than 40 countries around the world and to more than 30 states in US. This is an important fundament in the company’s own medical research and development program.